Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Multiple Sclerosis

Free Subscription 28.04.2025 1 Ann Neurol 1 Arch Phys Med Rehabil 1 BMC Neurol 1 J Neurol 2 J Neurol Neurosurg Psychiatry 4 Mult Scler 4 Neurology 1 PLoS Genet 1 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Neurol

1. MURARO PA, Zito A, Signori A, Sormani MP, et al
   Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study.
   Ann Neurol. 2025 Apr 19. doi: 10.1002/ana.27247.
   PubMed         Abstract available
   
   

   
   Arch Phys Med Rehabil

2. GRAVESTEIJN AS, Beckerman H, Willig M, Hulst HE, et al
   Effects of progressive resistance training on cardiovascular risk factors in people with progressive multiple sclerosis.
   Arch Phys Med Rehabil. 2025 Apr 21:S0003-9993(25)00653.
   PubMed         Abstract available
   
   

   
   BMC Neurol

3. LOFFLER A, Bereuter C, Delikaya M, Bellmann-Strobl J, et al
   Isolated Uhthoff phenomenon as first manifestation of multiple sclerosis: a case report.
   BMC Neurol. 2025;25:180.
   PubMed         Abstract available
   
   

   
   J Neurol

4. MAHMOUDI N, Renne J, Konen FF, Jendretzky KF, et al
   Added value of optic nerve lesions for multiple sclerosis diagnostic criteria.
   J Neurol. 2025;272:358.
   PubMed         Abstract available
   
   

   
   J Neurol Neurosurg Psychiatry

5. RUSKA B, Adamec I, Crnosija L, Gabelic T, et al
   Evolution of autonomic nervous system abnormalities in multiple sclerosis: a 6-year follow-up.
   J Neurol Neurosurg Psychiatry. 2025 Apr 24:jnnp-2024-335376.
   PubMed         Abstract available
   
   
6. ZICCARDI S, Guandalini M, Crescenzo F, Martinelli L, et al
   Cluster analysis showed long-term cognition can be predicted by looking at regional grey matter atrophy in the first two years of multiple sclerosis course.
   J Neurol Neurosurg Psychiatry. 2025 Apr 23:jnnp-2025-335925.
   PubMed         Abstract available
   
   

   
   Mult Scler

7. LAAKSO SM, Oh J, Raufdeen F, Jones A, et al
   Trigeminal neuralgia within the disease course of MS: Diagnostic and therapeutic implications from a multicenter cohort.
   Mult Scler. 2025;31:607-611.
   PubMed         Abstract available
   
   
8. BOBELNA B, Lobjois Q, Croitoru S, Jalkh E, et al
   Incidence of optic neuritis among Afro-descendant, a cohort study.
   Mult Scler. 2025;31:529-538.
   PubMed         Abstract available
   
   
9. KRAJNC N, Fottinger F, Ponleitner M, Kornek B, et al
   Diagnostic accuracy of inter-eye difference of ganglion cell layer alone in identifying optic neuritis in multiple sclerosis.
   Mult Scler. 2025 Apr 22:13524585251332895. doi: 10.1177/13524585251332895.
   PubMed         Abstract available
   
   
10. GREENWALD MA, Cancel Asencio HG, Dwyer J, Moss A, et al
    Differential Validity in the Written, Oral, and Electronic SDMT in Multiple Sclerosis.
    Mult Scler. 2025 Apr 24:13524585251330961. doi: 10.1177/13524585251330961.
    PubMed         Abstract available
    
    

    
    Neurology

11. VAN NEDERPELT DR, Bos L, Mattiesing RM, Strijbis EMM, et al
    Multiple Sclerosis-Specific Reference Curves for Brain Volumes to Explain Disease Severity.
    Neurology. 2025;104:e213618.
    PubMed         Abstract available
    
    
12. FOX RJ, Rudick RA
    A Newly Validated Gold Standard for Measuring Multiple Sclerosis Disability Worsening.
    Neurology. 2025;104:e213672.
    PubMed        
    
    
13. LANGER-GOULD A, Li BH, Smith JB, Kanter MH, et al
    Racial Inequities, Multiple Sclerosis, and Implementation of a Novel Treatment Algorithm at the Health System Level.
    Neurology. 2025;104:e213607.
    PubMed         Abstract available
    
    
14. KAPPOS L, Yiu S, Dahlke F, Coetzee T, et al
    Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials.
    Neurology. 2025;104:e213558.
    PubMed         Abstract available
    
    

    
    PLoS Genet

15. ASKAROVA A, Yaa RM, Marzi SJ, Nott A, et al
    Genetic risk for neurodegenerative conditions is linked to disease-specific microglial pathways.
    PLoS Genet. 2025;21:e1011407.
    PubMed         Abstract available
    
    

    
    PLoS One

16. ZANGENEH Z, Rostamian M, Motamedi H, Alvandi A, et al
    The potential effectiveness of probiotics in reducing multiple sclerosis progression in preclinical and clinical studies: A worldwide systematic review and meta-analysis.
    PLoS One. 2025;20:e0319755.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

17. YOON H, Gerdes LA, Beigel F, Sun Y, et al
    Multiple sclerosis and gut microbiota: Lachnospiraceae from the ileum of MS twins trigger MS-like disease in germfree transgenic mice-An unbiased functional study.
    Proc Natl Acad Sci U S A. 2025;122:e2419689122.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.